ENTX
Entera Bio Ltd.
$1.23
+6.03%
$60.6M
No data for this timeframe.
Vol
Market Cap$60.6M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (86%)
Insider Activity5B / 0S
Insider Net $$101.5K
Reddit Sentiment71° Bullish
SEC Reports5
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. L3·CIK 0001638097·Prev Close $1.16
Recent Activity
May 28, 2026
Press
Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO 2026, with new clin
Impact 6/10
May 28, 2026
announcement
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
<p align="justify">TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Ent
May 18, 2026
SEC
The SEC declared effective Entera Bio's S-3 registration statement (File No. 333-295710) on May 15, 2026, covering the r
EFFECT — Impact 3/10
May 8, 2026
SEC
Entera Bio filed an S-3 to register 19.6M ordinary shares for resale by BVF entities, issued in a $10M private placement
S-3 — Impact 3/10
May 8, 2026
SEC
Entera Bio reported Q1 2026 net loss of $3.5M ($-0.07/share), beating the $-0.08 consensus by 12.5%. The pre-revenue bio
8-K — Impact 5/10
May 7, 2026
Insider
Burshtein Gregory was granted 87,591 shares
Chief of R&D
May 7, 2026
Insider
Yaacov-Garbeli Dana was granted 58,394 shares
Chief Financial Officer
May 7, 2026
Insider
Galitzer Hillel was granted 72,993 shares
Chief Operating Officer
Price Targets
$9.00
+631.7% upside
Strong Buy
Current $1.23
Low $9.00
Median $9.00
High $9.00
1 analysts
$9.00
$9.00
Analyst Ratings
2Strong Buy
4Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
| Feb 9, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.08 ▲ +46.7% | $-0.08 — $-0.08 | -33% YoY | 1 |
| Next Q | $-0.08 ▲ +60.0% | $-0.08 — $-0.08 | -14% YoY | 1 |
| Current FY | $-0.34 ▲ +50.0% | $-0.34 — $-0.34 | -36% YoY | 1 |
| Next FY | $-0.57 | $-0.57 — $-0.57 | -68% YoY | 1 |
Latest Reports
BULLISH
Press
6/10
Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO 2026, with new clin
May 28, 2026
NEUTRAL
EFFECT
3/10
The SEC declared effective Entera Bio's S-3 registration statement (File No. 333-295710) on May 15, 2026, covering the r
May 18, 2026
NEUTRAL
S-3
3/10
Entera Bio filed an S-3 to register 19.6M ordinary shares for resale by BVF entities, issued in a $10M private placement
May 8, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 7, 2026 | Burshtein Gregory | A | $0.00 |
| May 7, 2026 | Yaacov-Garbeli Dana | A | $0.00 |
| May 7, 2026 | Galitzer Hillel | A | $0.00 |
| Mar 9, 2026 | Germano Geno | BUY | $26.0K |
| Mar 5, 2026 | Ellis Sean | BUY | $12.3K |
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
6 unique insiders with 8 transactions. Net insider value: $101.5K ($101.5K bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 7, 2026 | Burshtein Gregory | Chief of R&D | AWARD | 87,591 | — | — |
| May 7, 2026 | Yaacov-Garbeli Dana | Chief Financial Officer | AWARD | 58,394 | — | — |
| May 7, 2026 | Galitzer Hillel | Chief Operating Officer | AWARD | 72,993 | — | — |
| Mar 9, 2026 | Germano Geno J | Director | BUY | 20,000 | $1.30 | $26.0K |
| Mar 5, 2026 | Ellis Sean | Director | BUY | 10,000 | $1.23 | $12.3K |
| Feb 10, 2026 | Taitel Haya | Director | BUY | 7,500 | $1.48 | $11.1K |
| Feb 10, 2026 | Germano Geno J | Director | BUY | 20,000 | $1.49 | $29.8K |
| Feb 9, 2026 | Ellis Sean | Director | BUY | 18,000 | $1.24 | $22.3K |
5 SEC filing reports analyzed. Sentiment: 0 bullish, 1 bearish, 0 mixed, 4 neutral. Avg impact: 4.2/10.
NEUTRAL
EFFECT
3/10
The SEC declared effective Entera Bio's S-3 registration statement (File No. 333-295710) on May 15,
May 18, 2026
NEUTRAL
S-3
3/10
Entera Bio filed an S-3 to register 19.6M ordinary shares for resale by BVF entities, issued in a $1
May 8, 2026
NEUTRAL
8-K
5/10
Entera Bio reported Q1 2026 net loss of $3.5M ($-0.07/share), beating the $-0.08 consensus by 12.5%.
May 8, 2026
BEARISH
8-K
6/10
Entera Bio is raising capital through a private placement of $10.5 million in unregistered securitie
Apr 3, 2026
NEUTRAL
CLUSTER
4/10
Two Entera Bio directors, Germano Geno J and Ellis Sean, purchased shares in open-market transaction
Mar 11, 2026
BULLISH
6/10
Entera Bio announced that multiple abstracts across its oral peptide pipeline were accepted for ENDO
May 28, 2026
NEUTRAL
2/10
Entera Bio announced a virtual Key Opinion Leader webinar on April 20, 2026, to discuss the osteopor
Apr 14, 2026
MIXED
6/10
Entera Bio (ENTX) announced a $10.0 million private placement led by BVF Partners, issuing 7.83 mill
Apr 2, 2026
MIXED
5/10
Entera Bio reported financial results for 2025, showing increased net loss and R&D spending as it ad
Mar 27, 2026
Current analyst consensus: Strong Buy (86% buy). Based on 7 analysts: 2 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$9.00 mean target
+631.7% upside
Strong Buy (3.00)
$9.00 Low
$9.00 High
| Metric | Value |
|---|---|
| Current Price | $1.23 |
| Target Low | $9.00 |
| Target Mean | $9.00 |
| Target Median | $9.00 |
| Target High | $9.00 |
| # Analysts | 1 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.08 | $-0.08 | $-0.08 | -33.3% | +46.7% | 1↑ 0↓ | $0.0B | — | 1 |
| Next Q 2026-09-30 |
$-0.08 | $-0.08 | $-0.08 | -14.3% | +60.0% | 1↑ 0↓ | $0.0B | 0.0% | 1 |
| Current FY 2026-12-31 |
$-0.34 | $-0.34 | $-0.34 | -36.0% | +50.0% | 1↑ 0↓ | $0.0B | -100.0% | 1 |
| Next FY 2027-12-31 |
$-0.57 | $-0.57 | $-0.57 | -67.7% | — | 0↑ 1↓ | $0.0B | 0.0% | 1 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.080 | |
| 7d ago | $-0.090 | +0.010 |
| 30d ago | $-0.150 | +0.070 |
| 60d ago | $-0.150 | +0.070 |
| 90d ago | $-0.150 | +0.070 |
1 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 27, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Feb 9, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| May 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Apr 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Mar 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Feb 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% | |
| Jan 1, 2026 | 2 | 4 | 1 | 0 | 0 | 86% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
3 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Apr 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Apr 9, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Feb 6, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
May 28, 2026
announcement
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
<p align="justify">TEL AVIV, May 28, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (“Entera” or the “Company”), a leader in the developmen
May 8, 2026
earnings
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
<p align="center"><i>EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – Phase 3 protocol submi
May 8, 2026
earnings_calendar
ENTX Q1 2026 Earnings Scheduled — 2026-05-08
Apr 14, 2026
announcement
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
<p align="justify">TEL AVIV, Israel, April 14, 2026 (GLOBE NEWSWIRE) -- TEL AVIV, Israel, April 14, 2026 -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera”
Apr 2, 2026
announcement
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
<p align="justify">TEL AVIV, Israel, April 02, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (Nasdaq: ENTX) (“Entera” or the “Company”), a leader in the
Mar 27, 2026
earnings
Entera Bio Announces Full Year 2025 Financial Results and Provides Business Updates
<p align="center"><i>EB613, the first oral anabolic (bone building) peptide tablet for postmenopausal women with osteoporosis – FDA Type A endpoint al
Mar 27, 2026
earnings_calendar
ENTX Q4 2025 Earnings After Market Close — 2026-03-27
Mar 4, 2026
other
Entera Bio Submits Streamlined Phase 3 Protocol to Initiate Registrational Program for EB613 in Postmenopausal Women with Osteoporosis
<p><i>Phase 3 study designed with total hip BMD primary endpoint assessed at 12 months, rather than at 24 months</i></p>
Feb 26, 2026
other
Entera Bio to Participate in the Leerink Partners 2026 Global Healthcare Conference
<p align="justify">TEL AVIV, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) ("Entera" or the "Company"), a leader in the developme